Amyotrophic Lateral Sclerosis (ALS) Caused by Mutation in the TARDBP Gene

Amyotrophic Lateral Sclerosis (ALS) Caused by Mutation in the TARDBP Gene is a serious nerve disease that slowly damages the motor neurons—the cells that carry signals from the brain and spinal cord to muscles. As these cells die, muscles become weak, thin, and stiff. Over time, walking, hand use, speaking, swallowing, and breathing get harder. ALS does not affect thinking in many people, but some have changes in behavior or memory, especially when ALS overlaps with frontotemporal dementia (FTD).

The TARDBP gene gives instructions to make TDP-43, a protein that helps with RNA processing (the “instructions” used to make proteins). Certain changes (mutations) in TARDBP can cause ALS. In ALS, TDP-43 can move out of the cell nucleus and form clumps (aggregates) in the cell body. This “mislocalization” and clumping harm neurons and is seen in most ALS cases, not only the inherited ones. NCBI+2BioMed Central+2

TARDBP mutations are an uncommon genetic cause of ALS (a small fraction of all cases). Symptoms are similar to other forms of ALS, but there can be differences in speed and pattern. Most known TARDBP mutations lie in the protein’s C-terminal region. People with a suspected family history should be offered genetic counseling and testing. NCBI+1

ALS from TARDBP mutation is a form of motor neuron disease in which a change (mutation) in a single gene called TARDBP damages the nerve cells that control movement. TARDBP sits on chromosome 1p36.22 and makes a protein called TDP-43 that normally lives in the nucleus of the cell and helps manage many steps of RNA and protein production. In this disease, the mutant TDP-43 protein leaves the nucleus, builds up abnormally in the cell body (cytoplasm), and forms sticky clumps. This harms the motor neurons in the brain and spinal cord. Over time, muscles become weak, thin, stiff, and uncoordinated, leading to problems with walking, hand use, speech, swallowing, and breathing. Some people also develop changes in thinking or behavior because TARDBP disease can overlap with the frontotemporal dementia (FTD) spectrum. NCBI+1

Mutations in TARDBP are an autosomal dominant cause of ALS (a single altered copy is enough to increase risk). They explain about 3–5% of familial ALS and <1% of apparently sporadic ALS. Clinically, TARDBP-ALS usually looks like “typical” adult-onset ALS. NCBI+2NCBI+2

---

Other names

• TARDBP-related ALS

• TDP-43–related ALS

• ALS type 10 (ALS10)

• TARDBP-ALS-FTD spectrum disorder

• General synonyms for ALS: motor neurone disease (MND), Lou Gehrig’s disease, Charcot’s disease. Wikipedia+3NCBI+3National Organization for Rare Disorders+3

---

Types

These “types” are clinical shapes the illness can take. TARDBP-ALS can present in any of these patterns, just like other genetic or non-genetic ALS:

1. Limb-onset ALS – weakness begins in a hand or foot (most common).

2. Bulbar-onset ALS – speech and swallowing change first.

3. Respiratory-onset ALS – shortness of breath or orthopnea comes early.

4. Upper motor neuron–predominant – stiffness, brisk reflexes, Babinski sign are prominent.

5. Lower motor neuron–predominant – wasting, fasciculations, cramps dominate.

6. “Flail arm” syndrome – mainly proximal arm weakness.

7. “Flail leg” syndrome – distal leg weakness with foot drop pattern.

8. ALS with FTD – movement disease plus notable changes in behavior/executive function.

These phenotype labels are used across ALS and help clinicians describe what they see and plan testing; TARDBP disease falls within the same spectrum. PMC

---

Causes and contributors

In plain terms: a gene change starts a protein problem (TDP-43) that triggers cell stress and network failure in motor neurons. The items below are the main causes and contributors known today.

1. Pathogenic TARDBP mutation – typically a missense change in TDP-43’s C-terminal region; it disturbs protein behavior and is the core genetic cause. NCBI

2. TDP-43 mislocalization – protein leaks from the nucleus to the cytoplasm, where it should be scarce, and this starts early harm. BioMed Central

3. TDP-43 aggregation – abnormally phosphorylated/ubiquitinated TDP-43 forms toxic clumps inside neurons. NCBI

4. Loss of nuclear RNA control – with less TDP-43 in the nucleus, hundreds of RNAs are misspliced, including RNAs important for synapses and axons. Frontiers

5. Cytoplasmic gain-of-function toxicity – misfolded TDP-43 in the cytoplasm interferes with normal cell processes. BioMed Central

6. Stress-granule dysregulation – TDP-43 joins stress granules; disease mutations make these assemblies more persistent and harmful. Frontiers

7. Nucleocytoplasmic transport glitches – shuttling in/out of the nucleus is impaired, trapping proteins and RNAs in wrong places. PMC

8. Axonal transport failure – TDP-43 mutations disrupt transport of mRNA granules along axons, starving nerve endings of needed proteins. Frontiers

9. Prion-like spread – misfolded TDP-43 can seed neighboring cells, helping pathology spread along motor networks. Frontiers+2Nature+2

10. Autophagy/proteasome overload – the cell’s waste-clearance systems are overwhelmed, letting toxic proteins accumulate. PMC

11. Mitochondrial dysfunction – energy factories become less efficient and more oxidative, increasing neuron stress. PMC

12. Glutamate excitotoxicity & cortical hyperexcitability – overactive motor cortex and glutamate signaling add damage to motor neurons. Frontiers+1

13. Impaired DNA damage responses – abnormal TDP-43 is linked to increased DNA damage and weaker repair. BioMed Central

14. Neuroinflammation – microglia and astrocytes become reactive and can worsen motor neuron injury. PMC

15. Aging-related proteostasis decline – with age, protein quality control gets weaker, making neurons more vulnerable. Surgical Neurology International

16. Genetic background (modifiers) – other ALS genes (e.g., C9orf72, SOD1, FUS) and polygenic risk can shape onset and course. Frontiers

17. Head injury (risk factor) – a history of head trauma is associated with higher ALS risk in meta-analyses. Frontiers+1

18. Pesticide/solvent/metal exposures (risk factors) – multiple reviews link long-term exposure to higher ALS risk. Frontiers+2ScienceDirect+2

19. Smoking (risk factor) – several recent analyses suggest increased risk and worse prognosis, although findings vary. PMC+1

20. High lifetime physical load or military service (risk factor) – associated with ALS in some meta-analyses; mechanisms may include oxidative and metabolic stress. Frontiers

---

Common symptoms and signs

1. Gradual limb weakness – dropping objects, foot slap, or tripping due to weak hand/foot muscles; often starts on one side.

2. Muscle wasting (atrophy) – the weak muscles become visibly thinner over months.

3. Muscle twitches (fasciculations) – fine rippling movements under the skin, especially in hands, arms, shoulders, calves, or tongue.

4. Cramps and stiffness – painful cramps and increased tone; legs may feel “tight.”

5. Spasticity and brisk reflexes – overactive reflexes, clonus, Babinski sign; legs may catch or scissor.

6. Hand clumsiness – slower finger tasks, poor grip, trouble with keys, buttons, zippers, handwriting.

7. Foot drop – toes drag; ankle “flops” during walking; needs higher stepping to clear the foot.

8. Slurred or nasal speech (dysarthria) – words sound thick or effortful; voice may be quieter.

9. Swallowing trouble (dysphagia) – coughing with water, longer mealtimes, weight loss from poor intake.

10. Excess saliva – drooling because mouth and lip control are weaker.

11. Shortness of breath – first with exertion, later when lying flat (orthopnea) or during sleep.

12. Fatigue and weight loss – from muscle loss, breathing work, and higher energy needs.

13. Emotional lability (pseudobulbar affect) – sudden crying or laughing not fully in one’s control.

14. Cognitive or behavior change – poor planning, disinhibition, apathy, or language problems in ALS-FTD overlap (seen in a subset). NCBI

15. No major sensory loss – feeling, vision, and bowel/bladder typically remain normal until late.

---

Diagnostic tests

Doctors pull information from four buckets: (A) physical exam, (B) bedside/manual tests, (C) lab and pathology tests, and (D) electrodiagnostic & imaging. ALS is a clinical diagnosis backed by tests that support motor neuron involvement and exclude mimics. Modern “Gold Coast” criteria emphasize a progressive syndrome with both upper and lower motor neuron signs, supported by EMG, while ruling out alternatives. Taylor & Francis Online

A) Physical exam

1. Full neurologic examination – the core test. The clinician confirms both upper motor neuron signs (spasticity, brisk reflexes, Babinski) and lower motor neuron signs (wasting, fasciculations, weakness) across multiple body regions over time. This pattern is the hallmark of ALS. PMC

2. Bulbar and tongue exam – looks for tongue thinning, scalloping, fasciculations, weak palate, nasal speech, and a brisk jaw jerk (UMN sign). These findings support bulbar involvement. PMC

3. Gait and posture assessment – spastic or steppage gait, poor arm swing, and trouble with heel/toe walk point to motor tract and distal muscle weakness. PMC

4. Respiratory observation – shallow breaths, tachypnea, paradoxical abdominal motion, weak cough suggest diaphragm/intercostal involvement and trigger formal lung tests. PMC

5. Cognition/behavior screen – brief tools or history to look for FTD features (apathy, disinhibition, planning trouble) because TARDBP disease lies on the ALS-FTD spectrum. NCBI

B) Bedside / manual tests

6. Manual Muscle Testing (MRC scale) – the examiner grades strength from 0 to 5 by resisting specific movements. It tracks which muscles are failing and how fast. NCBI

7. Deep tendon reflexes and pathologic signs – tapping tendons and checking Babinski, Hoffman, clonus help document upper motor neuron involvement without machines. PMC

8. ALSFRS-R functional scale – a 12-item questionnaire that scores speech, swallowing, walking, hand use, and breathing; widely used to follow day-to-day function. PubMed

9. Single-breath count – you take a deep breath and count out loud; a quick bedside clue to breathing muscle weakness that prompts full pulmonary testing. PMC

10. Rapid alternating and fine motor tasks – finger tapping, peg tests, and writing tasks expose subtle hand slowness and incoordination from corticospinal and LMN loss. PMC

C) Laboratory & pathological tests

11. General blood/urine panels – to exclude mimics: CBC, CMP, ESR/CRP, thyroid, B12 and methylmalonic acid, copper/ceruloplasmin (to rule out thyroid disease, B12 deficiency, copper deficiency myelopathy). Medscape+1

12. Creatine kinase (CK) – may be mildly elevated from muscle breakdown but is nonspecific; helpful mainly to rule out primary muscle diseases. Medscape

13. Serologic tests for mimics – HIV, HTLV-1, Lyme, syphilis (RPR/VDRL), hepatitis, ANA/ANCA when indicated; some infections/immune neuropathies can imitate ALS. PMC

14. Serum protein electrophoresis with immunofixation – checks for monoclonal proteins (paraproteins) that point to neuropathies treatable with immunotherapy rather than ALS. PMC

15. Anti-GM1 antibodies – screens for multifocal motor neuropathy, a treatable mimic that can look like LMN-predominant ALS. Medscape

16. Neurofilament light (NfL) in blood or CSF – often elevated in ALS and can support an early diagnosis and prognosis, although it is not specific. Mayo Clinic

17. Genetic testing – today, all people with ALS should be offered testing that includes C9orf72 plus sequencing of SOD1, FUS, and TARDBP at minimum; counseling is recommended before/after. This confirms TARDBP disease when present. PMC

18. CSF analysis (when needed) – usually normal in ALS, but helps exclude inflammation, infection, or other diagnoses when the story is atypical. PMC

D) Electrodiagnostic & imaging tests

19. Nerve conduction studies (NCS) – show normal sensory responses and reduced motor responses without demyelinating features; help rule out neuropathies. PMC

20. Needle electromyography (EMG) – the key supportive test: reveals active denervation (fibrillation potentials, positive sharp waves) and chronic reinnervation in multiple body regions, including muscles that look normal on exam. PMC

21. Transcranial magnetic stimulation (TMS) – research and specialty centers use cortical hyperexcitability measures that can help identify upper motor neuron involvement early. Frontiers

22. Motor Unit Number Estimation / Index (MUNE/MUNIX) – electrophysiology methods that estimate how many motor units remain; useful to track progression and in trials. Nature

23. Phrenic nerve conduction or diaphragm ultrasound – evaluates breathing muscle innervation and function when respiratory symptoms appear. Radiopaedia

24. Pulmonary function tests (FVC, SNIP) – forced vital capacity (FVC) and sniff nasal inspiratory pressure (SNIP) quantify respiratory muscle strength and guide timing of breathing support. Radiopaedia+1

25. MRI of brain and spinal cord – mainly to exclude other causes (structural lesions, myelopathy). Sometimes it shows corticospinal tract signal changes supportive of ALS but not diagnostic. AJR Online+1

Non-pharmacological treatments (therapies and others)

Each item includes: purpose (why), mechanism (how it helps). (Concise here; I can expand any to ~150 words each.)

1. Multidisciplinary ALS clinic care
   Purpose: Coordinate neurology, respiratory, nutrition, rehab, speech, and social support. Improves survival and quality of life.
   Mechanism: Team anticipates problems early (breathing, swallowing, communication), times interventions, and supports caregivers.

2. Respiratory monitoring + noninvasive ventilation (NIV/BiPAP)
   Purpose: Ease breathlessness, improve sleep, prolong life.
   Mechanism: A mask-based ventilator supports weak breathing muscles, lowers carbon dioxide, and rests the diaphragm. NIV is linked with longer survival when used consistently. PMC+1

3. Airway secretion management
   Purpose: Reduce choking, coughing fits, and chest infections.
   Mechanism: Cough-assist machines, suction devices, humidification, and positioning help clear mucus; reduces aspiration risk.

4. Swallowing therapy (SLP-led)
   Purpose: Safer eating/drinking, fewer choking episodes.
   Mechanism: Texture modification, postural strategies (chin-tuck), pacing, and swallow exercises adjust to bulbar weakness.

5. Nutrition optimization
   Purpose: Maintain weight and strength; malnutrition worsens outcomes.
   Mechanism: High-calorie, high-protein meals, snacks, and supplements; early referral for feeding tube when needed. PEG feeding maintains weight and hydration. PMC

6. Percutaneous endoscopic gastrostomy (PEG) planning
   Purpose: Reliable nutrition/medication route when swallowing declines.
   Mechanism: A tube to the stomach allows safe feeding; done electively before respiratory function is too low. GIE Journal

7. Speech and augmentative/alternative communication (AAC)
   Purpose: Preserve communication and independence.
   Mechanism: Voice banking, text-to-speech devices, eye-gaze systems, and apps compensate for weak speech muscles.

8. Physical therapy (PT)
   Purpose: Maintain mobility, reduce stiffness/pain, prevent falls.
   Mechanism: Gentle range-of-motion, stretching, balance training, safe transfer techniques, energy-conservation strategies.

9. Occupational therapy (OT)
   Purpose: Protect independence in daily tasks.
   Mechanism: Adaptive tools (built-up grips, reachers), home safety changes, wheelchair/seating assessment.

10. Spasticity management (non-drug)
    Purpose: Ease stiffness and cramps.
    Mechanism: Daily stretching program, heat, splints, and trigger review (fatigue, dehydration).

11. Orthoses and mobility aids
    Purpose: Safer walking and energy saving.
    Mechanism: Ankle-foot orthoses for foot-drop, canes/walkers, custom wheelchairs with posture support.

12. Pressure-injury prevention
    Purpose: Avoid skin sores.
    Mechanism: Pressure-relief cushions/mattresses, regular position changes, skin checks, moisture control.

13. Fatigue and energy management
    Purpose: Increase “good hours” each day.
    Mechanism: Prioritize tasks, schedule rests, use labor-saving devices, cool environment.

14. Pain management (non-drug)
    Purpose: Relieve musculoskeletal pain.
    Mechanism: Positioning, heat/ice, gentle massage, stretching, and sleep optimization.

15. Sialorrhea management (non-drug)
    Purpose: Reduce drooling and aspiration risk.
    Mechanism: Posture, suction, oral care routines; (procedures/drugs below if needed).

16. Cognitive/behavioral support
    Purpose: Help if FTD-type changes occur.
    Mechanism: Caregiver education, routines, communication strategies, and mental health referral.

17. Psychological support
    Purpose: Reduce anxiety/depression, improve coping.
    Mechanism: Counseling, cognitive-behavioral strategies, mindfulness, peer support groups.

18. Advance care planning
    Purpose: Make care match personal values.
    Mechanism: Discuss ventilation, feeding tubes, hospitalizations, hospice, DNR/DNI, and appoint a health proxy.

19. Caregiver training and respite
    Purpose: Sustain safe home care and prevent burnout.
    Mechanism: Lift/transfer training, equipment use, short-break services.

20. Palliative care integration (early)
    Purpose: Improve comfort and quality of life throughout the illness.
    Mechanism: Symptom control, goals-of-care talks, support for patient and family.

---

Drug treatments

Note: Only a few drugs modestly change ALS progression; many others treat symptoms. Doses are typical adult starting points—clinicians tailor them. Tofersen is SOD1-specific (different gene); AMX0035/Relyvrio is withdrawn and not recommended for new patients. Federal Register+5American Academy of Neurology+5PMC+5

1. Riluzole
   Class: Glutamate release inhibitor. Dose/Time: 50 mg by mouth twice daily, long-term.
   Purpose: Modestly prolongs survival or time to ventilation.
   Mechanism: Reduces excitotoxic glutamate signaling in motor neurons.
   Side effects: Nausea, fatigue, elevated liver enzymes (check LFTs). Early use may help overall survival. American Academy of Neurology+2American Academy of Neurology+2

2. Edaravone (IV or oral)
   Class: Free-radical scavenger/antioxidant. Dose/Time: IV 60 mg daily in on/off cycles; oral suspension per label.
   Purpose: Slows functional decline in selected early-stage patients.
   Mechanism: Limits oxidative stress–related neuron injury.
   Side effects: Headache, gait issues, hypersensitivity; contains sulfites in some forms. Evidence is mixed; benefits may depend on stage/selection. PMC+1

3. Tofersen (for SOD1-ALS only, not TARDBP-ALS)
   Class: Antisense oligonucleotide. Dose/Time: Intrathecal loading then maintenance (per label).
   Purpose: Lowers SOD1 protein and neurofilament biomarkers; used when a SOD1 mutation is confirmed.
   Mechanism: Binds SOD1 mRNA to reduce toxic SOD1.
   Side effects: Headache, back pain, CSF pleocytosis. Not indicated for TARDBP-ALS. U.S. Food and Drug Administration+1

4. Dextromethorphan/quinidine
   Class: NMDA modulator + CYP inhibitor (Nuedexta). Dose: 20/10 mg twice daily.
   Purpose: Treats pseudobulbar affect (sudden laughing/crying).
   Mechanism: Alters glutamatergic/serotonergic signaling to stabilize affect.
   Side effects: Dizziness, diarrhea; avoid in prolonged QT.

5. Baclofen (oral)
   Class: GABA-B agonist antispasmodic. Dose: 5–10 mg three times daily, titrate.
   Purpose: Reduces spasticity and painful spasms.
   Mechanism: Damps spinal reflexes.
   Side effects: Sedation, weakness; taper to avoid withdrawal.

6. Tizanidine
   Class: α2-agonist antispasmodic. Dose: 2–4 mg at night, titrate.
   Purpose: Alternate or add-on for spasticity.
   Mechanism: Reduces excitatory neurotransmission.
   Side effects: Dry mouth, hypotension, LFT elevation.

7. Intrathecal baclofen (ITB) pump (drug + procedure)
   Class: GABA-B agonist delivered to CSF. Dose: Pump-titrated.
   Purpose: Severe spasticity not controlled by oral meds.
   Mechanism: High local spinal effect with fewer systemic side effects.
   Side effects: Catheter/pump complications, overdose/withdrawal risks.

8. Botulinum toxin injections (for focal spasticity or drooling)
   Class: Neuromuscular blocker. Dose: Site-dependent every 3–4 months.
   Purpose: Targets problem muscles or salivary glands.
   Mechanism: Blocks acetylcholine release.
   Side effects: Local weakness, dry mouth.

9. Glycopyrrolate
   Class: Anticholinergic. Dose: 1 mg twice daily, titrate.
   Purpose: Reduce drooling (sialorrhea).
   Mechanism: Lowers saliva production.
   Side effects: Dry mouth, constipation, urinary retention.

10. Atropine 1% sublingual drops
    Class: Anticholinergic. Dose: 1–2 drops under tongue up to TID.
    Purpose: On-demand drooling control.
    Mechanism: Blocks muscarinic receptors in salivary glands.
    Side effects: Dry mouth, blurred vision.

11. Scopolamine transdermal patch
    Class: Anticholinergic. Dose: 1 patch every 72 h.
    Purpose: Continuous drooling control.
    Mechanism: Central/peripheral antimuscarinic action.
    Side effects: Drowsiness, confusion (use with caution in older adults).

12. Amitriptyline (or nortriptyline)
    Class: Tricyclic antidepressant. Dose: 10–25 mg nightly.
    Purpose: Treats depression, drooling, and sleep issues.
    Mechanism: Inhibits reuptake of serotonin/norepinephrine; anticholinergic.
    Side effects: Dry mouth, constipation, QT prolongation.

13. SSRIs (e.g., sertraline, citalopram)
    Class: Antidepressants. Dose: Per standard.
    Purpose: Depression/anxiety.
    Mechanism: Boosts serotonin signaling.
    Side effects: GI upset, hyponatremia, sexual side effects.

14. Mirtazapine
    Class: NaSSA antidepressant. Dose: 7.5–15 mg nightly.
    Purpose: Depression + appetite/sleep benefits.
    Mechanism: Enhances noradrenergic/serotonergic tone.
    Side effects: Sedation, weight gain.

15. Quinine alternatives for cramps (e.g., mexiletine)
    Class: Sodium-channel blocker. Dose: 150–300 mg BID (specialist).
    Purpose: Severe muscle cramps.
    Mechanism: Stabilizes muscle membrane excitability.
    Side effects: GI upset, arrhythmia risk—cardiac review needed.

16. Gabapentin or pregabalin
    Class: Neuropathic pain modulators. Dose: Titrated.
    Purpose: Neuropathic pain, cramps, sleep.
    Mechanism: α2δ calcium-channel modulation.
    Side effects: Drowsiness, dizziness.

17. Short-acting opioids (low dose, carefully)
    Class: Analgesic. Dose: PRN for severe pain/dyspnea.
    Purpose: Comfort in advanced disease.
    Mechanism: μ-receptor analgesia, reduces air hunger.
    Side effects: Constipation, drowsiness—monitor closely.

18. Benzodiazepines (e.g., clonazepam) for anxiety/spasms
    Dose: Low dose at night. Purpose: Anxiety, spasms, sleep.
    Mechanism: GABA-A potentiation.
    Side effects: Sedation, falls—use sparingly.

19. Prokinetics/anti-reflux meds (e.g., PPI, metoclopramide)
    Purpose: Reflux and nausea that worsen feeding.
    Mechanism: Acid suppression or gastric emptying.
    Side effects: Per standard (e.g., EPS with metoclopramide—limit duration).

20. Vaccinations (influenza, pneumococcal)
    Purpose: Prevent infections that can be dangerous in ALS.
    Mechanism: Immune priming reduces pneumonia/flu risk.
    Side effects: Usual vaccine reactions.

Important contemporaneous notes:
• Riluzole remains first-line disease-modifying therapy. American Academy of Neurology
• Edaravone has mixed evidence but is FDA-approved; selection matters. PMC
• Tofersen is only for SOD1 mutations. U.S. Food and Drug Administration
• AMX0035/RELYVRIO: marketing withdrawn; not for new patients. Amylyx+1

---

Dietary molecular supplements

No supplement has proven to stop TARDBP-ALS. Use as adjuncts only, and discuss with your clinician to avoid interactions.

1. High-calorie oral nutrition
   Dose: Individualized calorie/protein targets.
   Function/Mechanism: Counters weight loss and muscle wasting; better nutrition links to better outcomes in ALS. (Feeding tube considered if oral intake is unsafe/insufficient.) PMC

2. Vitamin D
   Dose: Based on level (often 800–2000 IU/day).
   Function: Bone and immune support, may aid mood; deficiency is common in limited mobility.
   Mechanism: Nuclear receptor effects in muscle/neurons; ALS disease-modifying evidence is inconclusive.

3. Omega-3 fatty acids (EPA/DHA)
   Dose: ~1–2 g/day combined EPA/DHA.
   Function: Anti-inflammatory support and cardiovascular health.
   Mechanism: Cell membrane effects and resolvin pathways; ALS-specific benefit unproven.

4. Creatine
   Dose: 2–5 g/day.
   Function: Energy buffer in muscle; may help fatigue in some, but ALS trials have not shown clear benefit.
   Mechanism: Phosphocreatine system; no disease modification proven.

5. Coenzyme Q10
   Dose: 100–300 mg/day.
   Function: Mitochondrial cofactor; safe but ALS trials negative/neutral.
   Mechanism: Electron transport/antioxidant.

6. Acetyl-L-carnitine
   Dose: 1–2 g/day.
   Function: Fatty-acid transport into mitochondria; mixed evidence for fatigue.
   Mechanism: Mitochondrial energy support; ALS disease modification not proven.

7. Alpha-lipoic acid
   Dose: 300–600 mg/day.
   Function: Antioxidant recycling; neuropathy data exists, ALS data limited.
   Mechanism: Redox modulation.

8. Turmeric/curcumin preparations
   Dose: Per product (often 500–1000 mg curcuminoids/day).
   Function: Anti-inflammatory/antioxidant in general health; ALS evidence limited.
   Mechanism: NF-κB and Nrf2 pathways.

9. Resveratrol
   Dose: 100–500 mg/day.
   Function: Antioxidant; preclinical neuroprotection signals only.
   Mechanism: Sirtuin activation/mitochondrial signaling.

10. High-dose methylcobalamin (vitamin B12)
    Dose: Specialist protocols (e.g., high-dose IM in trials, not standard worldwide).
    Function: Possible motor neuron support; signals from Japanese studies but not a global standard.
    Mechanism: Methylation/neuronal repair; evidence remains inconclusive—discuss locally.

---

Immunity booster / regenerative / stem-cell drugs

No immune booster or stem-cell drug is approved to cure ALS. Stem-cell approaches and gene therapies are experimental; large trials so far have not shown clear, repeatable benefit in ALS. Always enroll through regulated trials.

1. Autologous mesenchymal stem cells (MSC-NTF/NurOwn®)
   Status: Failed to meet primary endpoint in phase 3; FDA did not approve. Investigational only.
   Function/Mechanism: Secretion of neurotrophic and anti-inflammatory factors.

2. Neural progenitor cell grafts
   Status: Early-phase studies only.
   Function/Mechanism: Attempt to replace/support motor neurons and glia.

3. AAV gene therapy (platform concept)
   Status: Practical only when a specific causal gene is targeted (e.g., SOD1/C9). Not applicable to TARDBP yet in routine care.
   Mechanism: Delivers antisense/CRISPR cargo to silence or correct toxic genes.

4. Low-dose IL-2 / immunomodulation
   Status: Experimental; aims to increase regulatory T-cells.
   Mechanism: Immune balance to reduce harmful inflammation.

5. Rho-kinase (ROCK) pathway inhibitors
   Status: Investigational neuroprotection.
   Mechanism: Cytoskeletal/axonal support; human efficacy unproven.

6. Neurotrophic factor cocktails
   Status: Various trials; no consistent clinical benefit so far.
   Mechanism: Support neuron survival signaling.

---

Procedures/surgeries

1. Percutaneous Endoscopic Gastrostomy (PEG)
   Procedure: A soft tube placed through the abdominal wall into the stomach using an endoscope.
   Why: Ensures safe nutrition, hydration, and medication delivery when swallowing is unsafe/insufficient; ideally placed before breathing is too weak. GIE Journal+1

2. Radiologically Inserted Gastrostomy (RIG/PRG)
   Procedure: Feeding tube placed under imaging guidance (no endoscope).
   Why: Alternative route for people not suitable for endoscopy.

3. Tracheostomy with invasive ventilation
   Procedure: A breathing tube through the neck attached to a ventilator.
   Why: For advanced respiratory failure when long-term full-time ventilation is chosen; requires intensive home care planning.

4. Intrathecal baclofen pump implantation
   Procedure: A small pump under the skin delivers baclofen into CSF via a catheter.
   Why: For severe spasticity not controlled by oral therapy; improves comfort and care.

5. Salivary gland duct ligation or gland procedures (selected cases)
   Procedure: ENT surgery to reduce saliva flow (sometimes radiation is used instead of surgery).
   Why: When drooling remains severe despite medicines and botulinum injections.

Note: Diaphragm pacing is not recommended in ALS; trials showed harm or no benefit. BioMed Central

---

Prevention

ALS itself cannot be prevented, but complications can be:

1. Keep vaccinations up to date (flu, pneumococcal).

2. Early NIV when indicated to prevent nocturnal hypoventilation. PMC

3. Plan nutrition early; don’t wait for major weight loss. PMC

4. Texture-modified diets and swallow strategies to prevent aspiration.

5. Consider PEG before breathing is too weak. GIE Journal

6. Pressure-relief routines and skin care to prevent sores.

7. Home fall-proofing and correct mobility aids to prevent injuries.

8. Oral care and secretion management to prevent pneumonia.

9. Energy-conservation to prevent exhaustion and caregiver strain.

10. Advance care planning to prevent crisis decisions.

---

When to see doctors

• New muscle weakness, falls, slurred speech, or swallowing trouble.

• Breathlessness at rest or when lying flat, morning headaches, poor sleep—possible hypoventilation (pulmonology/respiratory therapy).

• Unintended weight loss or repeated choking—nutrition and SLP.

• Uncontrolled drooling, severe cramps/spasticity, or pain—neurology/rehab for adjustment of meds/equipment.

• Sudden mood changes or uncontrolled laughing/crying—neurology/mental health.

• Family history of ALS or early symptoms—genetic counseling/testing to clarify risks and options. NCBI

---

What to eat and what to avoid

1. Eat: Frequent small, high-calorie meals and snacks; add healthy oils, nut butters, full-fat dairy if tolerated.

2. Eat: High-protein foods (eggs, fish, poultry, legumes, dairy) to protect muscle.

3. Eat: Soft, moist textures if swallowing is difficult; use sauces/gravies.

4. Eat/Drink: Thickened liquids if advised by SLP.

5. Drink: Adequate fluids; consider high-calorie shakes.

6. Avoid: Dry, crumbly foods (e.g., crackers) if choking risk.

7. Avoid: Mixed-texture foods (soups with chunks) if advised.

8. Avoid: Alcohol excess—worsens balance and sleep.

9. Avoid: Unproven “miracle cures” and costly supplements without clinician review.

10. Plan: If meals are stressful or too long, discuss PEG feeding to maintain strength and safety. PMC

---

Frequently asked questions

1. Is TARDBP-ALS different from regular ALS?
   It’s a genetic form caused by a TARDBP mutation. Symptoms are similar to other ALS forms. TDP-43 clumps are common in most ALS, not just the genetic kind. BioMed Central

2. Does everyone with a TARDBP mutation get ALS?
   No. Risk is high but not 100%. A genetics team can explain personal risk.

3. How is TARDBP-ALS diagnosed?
   By clinical exam, EMG/NCS, ruling out mimics, and genetic testing showing a TARDBP variant (plus family history in some). NCBI

4. What medicines slow ALS?
   Riluzole for most people; edaravone for some; tofersen only for SOD1-ALS; AMX0035 is withdrawn. Amylyx+3American Academy of Neurology+3PMC+3

5. Can breathing machines really help?
   Yes. Non-invasive ventilation improves symptoms and survival when used regularly. PMC

6. When should we talk about a feeding tube?
   Early—before major weight loss or dangerous choking. It helps keep weight and energy up. GIE Journal+1

7. Are stem-cell treatments available?
   Not as approved, proven therapy. Trials so far have not shown consistent benefit; join only regulated studies.

8. Will exercise make me worse?
   Gentle, supervised activity and stretching can help; avoid heavy, tiring workouts that worsen weakness.

9. What about vitamins and supplements?
   Use to meet basic needs (e.g., vitamin D), but none is proven to stop ALS. Discuss with your team to avoid interactions.

10. Can ALS affect thinking or behavior?
    Some people develop FTD-type changes. Screening helps tailor care.

11. How long can people live with ALS?
    It varies. Average is 3–5 years from symptom start, but many live longer, especially with good respiratory and nutritional care.

12. Should my family be tested?
    Genetic counseling first. Testing depends on age, plans, and the exact mutation found. NCBI

13. Is diaphragm pacing helpful?
    No—studies showed harm or no benefit in ALS. BioMed Central

14. Does early treatment matter?
    Yes. Early riluzole, timely NIV, and nutrition planning improve outcomes and comfort. PMC+1

15. Where can I read reliable updates?
    AAN guidelines, FDA announcements, and national ALS organizations keep up-to-date resources. American Academy of Neurology+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 15, 2025.

PDF Documents For This Disease Condition References